So, within the generic companies, from the US point of view, Cipla delivered a very good set of results supported by the niche launches. An...

Cipla shares rose by 2.4% to Rs 1,483.40 on Tuesday after Kotak Institutional Equities upgraded the stock from "add" to "buy," with a targe...

The steady generic pricing is a tailwind and execution of key launches like gAbraxane for Cipla will determine the path of US sales in 2025.

Cipla's shares surged 9.8% after the USFDA classified its Goa facility inspection as Voluntary Action Indicated (VAI), allowing for critica...

Cipla recorded an 8% growth in sales on the back of the launch of the generic version of Revlimid and gained market share in lanreotide, al...

“Coming to the complex generics opportunity, Cipla and Lupin are most exposed. We like Cipla more than Lupin because at least in the near t...

Cipla reported a multi-quarter high of $179 million in revenue and 25% YoY growth led by the successful launch of a generic version of the ...

“When it comes to pharma we are not seeing secular growth. While India can be a secular growth story, we believe the US would not be and th...

Founded in 1935 by Hamied’s grandfather in then-colonial Bombay, Cipla made its name globally by pioneering the sale of cheap, generic HIV ...

Currently, the m-cap of the company stands at Rs 1,508.61 crore.

The partnership will develop and market a generic version of Celgene's ABRAXANE which is used in treatments of breast and lung cancers.

The application was refused on the grounds of the US firm's claims lacking of inventive step, not being patentable and insufficiency, legal...

Panacea Biotec will soon launch a generic version of Abraxis Bioscience's breast cancer medicine Abraxane at half the price of the original...

The original maker of the drug, American firm Abraxis Bioscience had complained about the side effects of Natco’s version of the medicine.

The country’s top drug regulator plans to initiate criminal proceedings against Hyderabad-based Natco Pharma for selling “substandard” brea...

The drug regulator (DCGI) acted afer the US firm filed a written complaint citing serious side-effects that the generic may cause.

AstraZeneca posted a 42 per cent rise in first quarter net profit on Thursday, boosted by sales of its heart drug Toprol-XL in the United S...